— Generic drugmaker Sanofi (NASDAQ: SNY) reported net income of EUR 1.77 billion or EUR 1.49 per share for the third quarter, on IFRS basis, down 23.% and 18.6% respectively from last year
— IFRS net sales increased 1.1% year-over-year to EUR 9.5 billion, on a reported basis
— Sanofi Genzyme sales rose 19.5% annually, aided by continued strong uptake of Dupixent
— Vaccine sales decreased 9.8%, reflecting anticipated weighing of flu vaccine supply towards year-end
— Expects business earnings to grow about 5%, on a constant-currency basis and excluding one-off items, in fiscal 2019
— During the quarter, European Commission approved Dupixent for severe chronic rhinosinusitis
— Achieved positive results from advanced-stage study on Dupixent for severe atopic dermatitis in children
Most Popular
NKE Q2 Earnings Preview: Can Nike maintain the recovery momentum?
Sneaker giant NIKE, Inc. (NYSE: NKE) entered the fiscal year facing heightened competition and shifting consumer preferences. Its upcoming second-quarter results are expected to reflect these evolving industry dynamics and
Earnings Preview: Conagra Brands’ (CAG) sales and earnings projected to decline in Q2 2026
Shares of Conagra Brands, Inc. (NYSE: CAG) rose 1% on Friday. The stock has dropped 7% in the past three months. The branded food company is slated to report its
Costco (COST) reports strong growth in Q1 FY26 earnings; revenue up 8%
Costco Wholesale Corporation (NASDAQ: COST) has reported an increase in net income for the first quarter of fiscal 2026. Revenues grew 8.3% year-over-year. The Issaquah, Washington-headquartered warehouse giant’s total revenues
Comments
Comments are closed.